Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia

Published:2022-10 Issue:22 Volume:128 Page:3951-3958
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Cheng Fang¹²^ORCID,Zeng Fang¹²,Li Qiang¹²,Cui Zheng¹²,Chen Yilin³,Li Weiming³^ORCID,Zhang Yu¹²

Affiliation:

1. Department of Pharmacy Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

2. Hubei Province Clinical Research Center for Precision Medicine for Critical Illness Wuhan China

3. Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34478

Reference30 articles.

1. How I treat newly diagnosed chronic myeloid leukemia in 2015

2. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

3. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia;International Immunopharmacology;2024-05

2. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?;Expert Review of Clinical Pharmacology;2024-02-12

3. Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China;Therapeutic Advances in Hematology;2024-01

4. Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia;Pharmacology Research & Perspectives;2023-07-07

5. Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics;Cancers;2023-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3